Bristol Myers Squibb is ramping up its Indian operations by launching new drugs faster and more effectively through a $100 million AI commercialisation initiative. The company has introduced treatments such as mavacamten for hypertrophic cardiomyopathy and expanded its oncology portfolio. Its AI hub, operated in partnership with Accenture in Mumbai, drastically shortens prescriber updates from months to weeks and personalises engagement with healthcare providers. This transformation supports BMS's global ambitions and prepares for patent cliffs expected later this decade, ensuring sustained growth through a robust pipeline of novel therapies.